Tag Directory / BIOTECH     showing 1–8 of 8

for: Saturday, February 14, 2026



Extracorporeal liver cross-circulation using transgenic xenogeneic pig livers with brain-dead human decedents / Nature

Abraham Shaked / nature - Nature Medicine, Published online: 09 February 2026; doi:10.1038/s41591-025-04196-3In a study of four brain-dead human decedents, extracorporeal liver cross-circulation using genetically modified pig livers provides essential hepatic functions, supporting…

#healthcare #publichealth #governmentpolicy #biotech #fda #medicaldevices

Vascularized liver tissueoid-on-a-chip models regeneration and transplant rejection

20 days / medicalxpress

Extracorporeal cross-circulation with genetically modified pig livers in a human decedent model

28 days / nature

A new window into hemodialysis: How optical sensors could make treatment safer

4 wks / medicalxpress

Extracorporeal liver cross-circulation using transgenic xenogeneic pig livers with brain-dead human decedents

4 wks / nature / Abraham Shaked

Saturday, February 14, 2026, 10:21 am / permalink 19188 / 4 stories in 25 days


New FDA-Approved Device Uses Electric Fields to Treat Pancreatic Cancer / Discover

discovermagazine - Learn more about the newly approved wearable treatment that disrupts pancreatic cancer tumor growth while letting patients continue daily life at home.

#healthcare #publichealth #biotech #fda #digitalhealth #medicaldevices #oncology #pancreaticcancer

Optune Pax Secures FDA Approval in Locally Advanced Pancreatic Cancer, Lifting NVCR 19%

20 days / oncodaily

FDA approves noninvasive Optune Pax device for advanced pancreatic cancer

21 days / medicalxpress

Immunotherapy plus chemotherapy before surgery shows promise for pancreatic cancer

21 days / medicalxpress

NAPOLI 3 Subgroup Analysis: NALIRIFOX in Older Patients With Metastatic Pancreatic Cancer

22 days / oncodaily

Sensing local fibers in pancreatic tumors, cancer cells 'choose' to either grow or tolerate treatment

23 days / medicalxpress

Nina Niu Sanford Shares Update on NRG-GI011 Pancreas Cancer Trial

23 days / oncodaily

Shaalan Beg: The Role of Novel Radiation Methods for Locally Advanced Pancreatic Cancer

24 days / oncodaily

Erdinç Nayır: FDA Approved TTFields Plus Chemotherapy for Locally Advanced Pancreatic Cancer

24 days / oncodaily

Scientists find nerves actively fuel pancreatic cancer

24 days / sciencedaily

New FDA-Approved Device Uses Electric Fields to Treat Pancreatic Cancer

25 days / discovermagazine

Allyson J. Ocean: Electrifying News for Patients with Pancreatic Cancer

25 days / oncodaily

Allyson J. Ocean: When Pancreatic Cancer Meets a New Force of Innovation

25 days / oncodaily

Saturday, February 14, 2026, 10:21 am / permalink 19187 / 12 stories in 25 days


HPV cancer vaccine slows tumor growth and extends survival in preclinical model / Medical Express

medicalxpress - Throughout the past decade, Northwestern University scientists have uncovered a striking principle of vaccine design: Performance depends not only on vaccine components but also on vaccine structure. After proving this concept across multiple studies, the…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

This reengineered HPV vaccine trains T cells to hunt down cancer

21 days / sciencedaily

Cancer virus imaging helps uncover potential therapeutic targets

22 days / medicalxpress

Dual brakes on T-cells: New targets found to boost immunity in chronic infections

23 days / medicalxpress

Cancer vaccine shows promise against HPV-related throat tumors in early study

27 days / livescience

HPV cancer vaccine slows tumor growth and extends survival in preclinical model

27 days / medicalxpress

Saturday, February 14, 2026, 5:21 am / permalink 19182 / 5 stories in 25 days


FDA clears 1st blood test for Alzheimer’s in primary care / Beckers

Ella Jeffries / beckershospitalreview - The first FDA-cleared blood test to assess Alzheimer’s disease in primary care is now available for patients age 55 and older with symptoms of cognitive decline. The test aims to help clinicians rule out Alzheimer’s by identifying individuals unlikely to …

#healthcare #publichealth #governmentpolicy #biotech #fda

A possible Alzheimer's biomarker? Why REST protein levels are drawing attention

20 days / medicalxpress

J&J pauses patient recruitment in mid-stage trial of AC Immune’s Alzheimer’s drug

20 days / endpoints / Elizabeth Cairns

Blood test 'clocks' can predict when Alzheimer's symptoms will start

20 days / medicalxpress

Viagra and shingles vaccine show surprising promise against Alzheimer’s

21 days / sciencedaily

Paragon's new biotech Korsana tackles Alzheimer's like Roche

21 days / endpoints / Kyle LaHucik

Air pollution may directly contribute to Alzheimer's disease

21 days / medicalxpress

The good side of a side effect: Brain swelling during Alzheimer's treatment may signal strong response

21 days / medicalxpress

Connecting the dots between cause-effect events in Alzheimer's disease

22 days / medicalxpress

Alzheimer's gene boosts seizures, but pathway can be targeted, study finds

22 days / medicalxpress

Senescent astrocytes discovered in Alzheimer's brains point to new treatment targets

22 days / medicalxpress

Hearing loss and cognitive decline in presbycusis may be linked via neural activity fluctuations, cell death

22 days / medicalxpress

Neurodegenerative diseases need more mechanism-informed trials

23 days / nature

A quantitative DOPA decarboxylase biomarker for diagnosis in Lewy body disorders

23 days / nature / Katharina Bolsewig

Your morning coffee might protect your brain as you age. Here's the sweet spot

24 days / medicalxpress

Menopause, hormones and the brain: How hormone therapy could help protect against Alzheimer's

25 days / medicalxpress

Blood-based tests show strong promise for dementia diagnosis—but population diversity matters

25 days / medicalxpress

FDA clears 1st blood test for Alzheimer’s in primary care

28 days / beckershospitalreview / Ella Jeffries

Capillary blood sampling for detecting biomarkers of Alzheimer’s disease

28 days / nature

Saturday, February 14, 2026, 4:21 am / permalink 19180 / 18 stories in 25 days


Studies test whether gene-editing can fix high cholesterol. For now, take your medicine / Medical Express

medicalxpress - Scientists are testing an entirely new way to fight heart disease: a gene-editing treatment that might offer a one-time fix for high cholesterol.

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

Nanoparticle-based gene editing could expand treatment options for cystic fibrosis

21 days / medicalxpress

Massive study finds most statin side effects aren’t caused by the drugs

24 days / sciencedaily

Studies test whether gene-editing can fix high cholesterol. For now, take your medicine

27 days / go

Studies test whether gene-editing can fix high cholesterol. For now, take your medicine

27 days / medicalxpress

Saturday, February 14, 2026, 3:21 am / permalink 19179 / 4 stories in 25 days


Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B / MedCity

Frank Vinluan / medcitynews - Orna Therapeutics brings Eli Lilly an in vivo cell therapy ready for Phase 1 testing as a potential treatment for autoimmune diseases. Lilly is now the latest pharma company to use M&A to enter this growing field, following deals made in the past year by …

#healthcare #pharmaceuticals #elililly #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment

Al-Ola Abdallah: Discussing Updates of CAR-T in Malignant Hematology with Nausheen Ahmed

20 days / oncodaily

J&J pours $1B into new cell therapy site in Pennsylvania

20 days / endpoints / Nicole DeFeudis

Lilly licenses CSL’s IL-6 immuno-inflammatory antibody for $100M upfront

21 days / endpoints / Elizabeth Cairns

One stem cell generates 14 million tumor-killing NK cells in major cancer breakthrough

21 days / sciencedaily

Caroline Pothet: The 2026 Workplan of the Committee For Advanced Therapies is Available

22 days / oncodaily

Eddie Cliff: Why CAR T Infusion Timing Doesn’t Change Outcomes in LBCL

22 days / oncodaily

Optimizing CAR T-cell therapy to tackle solid tumors

22 days / medicalxpress

Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B

29 days / medcitynews / Frank Vinluan

Lilly joins in vivo CAR-T sprint with $2.4B Orna acquisition

4 wks / endpoints / Kyle LaHucik

Saturday, February 14, 2026, 3:21 am / permalink 19178 / 9 stories in 25 days


Sanofi's Paul Hudson out, with Belén Garijo to step in as new CEO / Endpoints

Reynald Castañeda / endpoints - Paul Hudson is stepping down from his post as CEO of Sanofi, and his last day will be Feb. 17. The French drugmaker's board decided not to renew Hudson's mandate on ...

#healthcare #pharmaceuticals #biotech #drugdevelopment

Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and more

25 days / endpoints / Nicole DeFeudis

Sanofi's Paul Hudson out, with Belén Garijo to step in as new CEO

27 days / endpoints / Reynald Castañeda

Medical neglect contributed to mother's death, inquest finds

27 days / bbc

Saturday, February 14, 2026, 3:20 am / permalink 19177 / 3 stories in 25 days


BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing / MedCity

Frank Vinluan / medcitynews - Infigratinib achieved statistically significant improvement in growth rate and body composition in a Phase 3 clinical trial that tested the BridgeBio Pharma drug in achondroplasia, the most common form of dwarfism. Regulatory submissions are planned for l…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda

BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing

26 days / medcitynews / Frank Vinluan

BridgeBio's dwarfism drug succeeds in Phase 3, adding to recent late-stage wins

27 days / endpoints / Max Gelman

Saturday, February 14, 2026, 12:22 am / permalink 19171 / 2 stories in 25 days


Back to Top


BIOTECH Heatmap

90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.



More Top Stories...

FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...


NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.